News
18h
Stocktwits on MSNNurix Therapeutics Posts Better-Than-Expected Q2 Results; Revenue Soars on Sanofi and Gilead PaymentsShares of Nurix Therapeutics jumped on Wednesday after the biotech company reported stronger-than-expected results for the ...
Sanofi is sponsoring the event for the second year in a row, which brings together 1,000 transplant recipients and live donors to compete.
16d
Zacks Investment Research on MSNSanofi Trades Below 50 & 200-Day Moving Averages: Time to Buy the Dip?Sanofi’s SNY stock has been trading below its 200-day and 50-day moving averages since early June. On June 23, the stock’s ...
Sanofi has doubled down on its partnership with Adagene, investing $25 million in the biotech, taking up its option on a ...
8d
GlobalData on MSNSanofi agrees to invest $25m in AdageneSanofi has agreed to invest up to $25m in Adagene, which will enable the latter to fund its research and development (R&D) ...
Transplants can be life-saving – but for many, the journey doesn’t end there. Up to 40% of people receiving a stem cell or bone marrow transplant will go on to develop a serious complication known as ...
Explore more
Sanofi to exercise option on third SAFEbody discovery program and sponsor combination clinical trial with muzastotug - ...
"Campus Sanofi is a non-profit offering for healthcare professionals," says Olba. Nevertheless, having the name of a pharma company in such an initiative can be a barrier for doctors taking part, ...
Sino-American antibody company Adagene (Nasdaq: ADAG) has announced a strategic investment and option exercise by Sanofi ...
Sanofi agreed to invest up to $25 million in the clinical-stage biotechnology company. Adagene said it plans to use the proceeds to fund its research and development activities, including clinical ...
NEW YORK CITY, NY / ACCESS Newswire / July 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ:SNY). Such investors are advised to cont ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results